We are live on ! Find out more
VA

VR Adviser Portfolio holdings

AUM $2.68B
1-Year Est. Return 422.73%
This Fund
S&P 500
This Quarter Est. Return
+25.77%
1 Year Est. Return
+422.73%
3 Year Est. Return
+1,447.09%
5 Year Est. Return
+3,249.52%
10 Year Est. Return
–
AUM
$1.91B
AUM Growth
+$339M
Cap. Flow
+$72.2M
Cap. Flow %
3.78%
Top 10 Hldgs %
65.6%
Holding
38
New
3
Increased
6
Reduced
6
Closed
–

Top Buys

Rank Stock Value
1
ORKA
Oruka Therapeutics
ORKA
+$105M
2
ARTV
Artiva Biotherapeutics
ARTV
+$18.7M
3
CASI
CASI Pharmaceuticals
CASI
+$5.66M
4
ENGN icon
enGene Therapeutics
ENGN
+$5.5M
5
APLT
Applied Therapeutics
APLT
+$1.66M

Top Sells

Rank Stock Value
1
MRUS
Merus
MRUS
+$18.5M
2
EWTX icon
Edgewise Therapeutics
EWTX
+$16.3M
3
ZURA icon
Zura Bio
ZURA
+$14.9M
4
DNTH icon
Dianthus Therapeutics
DNTH
+$9.75M
5
ARVN icon
Arvinas
ARVN
+$4.53M

Sector Composition

Rank Sector Weight
1 Healthcare 99.61%
2 Financials 0.39%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TSHA icon
26
Taysha Gene Therapies
TSHA
$1.68B
$18.1M 0.95%
9,000,000
– –
ABVX
27
Abivax
ABVX
$10.9B
$15.5M 0.81%
1,345,780
– –
TRVI icon
28
Trevi Therapeutics
TRVI
$2.59B
$11.4M 0.6%
3,422,656
+19
+0% +$56
ARVN icon
29
Arvinas
ARVN
$518M
$11.2M 0.59%
454,450
-173,338
-28% -$4.53M
ADVM
30
DELISTED
Adverum Biotechnologies
ADVM
$10.3M 0.54%
1,467,048
– –
IPSC icon
31
Century Therapeutics
IPSC
$364M
$9.22M 0.48%
5,389,259
– –
ZURA icon
32
Zura Bio
ZURA
$516M
$8.21M 0.43%
2,023,166
-4,000,000
-66% -$14.9M
PCSC
33
DELISTED
Perceptive Capital Solutions
PCSC
$7.51M 0.39%
750,000
– –
CABA icon
34
Cabaletta Bio
CABA
$437M
$7.38M 0.39%
1,563,952
– –
CASI
35
DELISTED
CASI Pharmaceuticals
CASI
$6.08M 0.32%
987,259
+875,573
+784% +$5.66M
TNYA icon
36
Tenaya Therapeutics
TNYA
$161M
$3M 0.16%
1,555,556
– –
TIL icon
37
Instil Bio
TIL
$48.3M
$2.23M 0.12%
+33,177
New +$781K
TENX icon
38
Tenax Therapeutics
TENX
$363M
$721K 0.04%
+208,333
New +$755K
1
2

Similar funds

MMEA
Main Management ETF Advisors San Francisco, California $2.68B AUM 24.27% 1-Year Est. Return
WGI
Westwood Global Investments Boston, Massachusetts $2.68B AUM 76.4% 1-Year Est. Return
TCAM
Turtle Creek Asset Management Toronto, Ontario, Canada $2.67B AUM 0.64% 1-Year Est. Return
SFI
Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return
HC
Henshaw Capital Woburn, Massachusetts $2.7B AUM 29.67% 1-Year Est. Return
CI
Capital International Los Angeles, California $2.7B AUM 31.08% 1-Year Est. Return
PCA
Pallas Capital Advisors Braintree, Massachusetts $2.66B AUM 22.31% 1-Year Est. Return
LP
Longaeva Partners Chicago, Illinois $2.7B AUM 37.16% 1-Year Est. Return

VR Adviser's Q3 2024 Portfolio in Review

As of Q3 2024, VR Adviser held 38 positions worth $1.91B, up 22% from $1.57B the previous quarter. Its ten largest holdings account for 66% of the portfolio.

VR Adviser deployed $72.2M of net new capital in Q3 2024, opening 3 new positions and adding to 6 existing holdings. Its largest new stake was Artiva Biotherapeutics: 1,609,569 shares worth $24.9M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Merus, an estimated $18.5M trimmed.

  • VR Adviser's largest Q3 2024 buy was Artiva Biotherapeutics: 1,609,569 shares worth $24.9M.
  • VR Adviser added most to Oruka Therapeutics in Q3 2024, an estimated $105M increase.
  • VR Adviser's biggest Q3 2024 reduction was Merus, cutting an estimated $18.5M.
  • VR Adviser's ten largest holdings make up 66% of its $1.91B portfolio in Q3 2024.
  • VR Adviser opened 3 new positions and closed 0 in Q3 2024.
  • VR Adviser's portfolio value rose 22% quarter-over-quarter to $1.91B.

Based on VR Adviser's 13F filing for Q3 2024, filed 14 Nov 2024.